| Examiner | Number of Cases | 3YGR |
|---|---|---|
| Examiner Bell | 71 | 0% |
| Examiner Chandrakumar | 798 | 71% |
| Examiner English | 7 | 0% |
| Examiner Hutter | 95 | 41% |
| Examiner Ismail | 26 | 0% |
| Examiner Kenyon | 592 | 69% |
| Examiner Kosar (SPE) | 12 | 0% |
| Examiner Mahlum | 14 | 0% |
| Examiner Mcanany | 13 | 0% |
| Examiner Oh | 634 | 85% |
| Examiner Rozof | 765 | 81% |
| Examiner Rzeczycki | 17 | 0% |
| Examiner Seaman | 526 | 82% |
| Examiner Tao | 0 | 0% |
| Art Unit 1625 | 3570 | 73% |
| Number | Class Description |
|---|---|
| 514 | Drug, bio-affecting and body treating compositions |
| 546 | Organic compounds -- part of the class 532-570 series |
| 549 | Organic compounds -- part of the class 532-570 series |
| 544 | Organic compounds -- part of the class 532-570 series |
| 548 | Organic compounds -- part of the class 532-570 series |
| 540 | Organic compounds -- part of the class 532-570 series |
| 424 | Drug, bio-affecting and body treating compositions |
| 435 | Chemistry: molecular biology and microbiology |
| 558 | Organic compounds -- part of the class 532-570 series |
| 502 | Catalyst, solid sorbent, or support therefor: product or process of making |
Art Unit 1625's grant rate is higher than that of Group 1620 and lower than that of the USPTO.
Below is the grant rate timeline for Art Unit 1625, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.
Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.